Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00152828

Celebrex - Cervix: Celecoxib in the Treatment of Patients With Locally Advanced Carcinoma of the Cervix

A Phase I/II Trial of the Cyclooxygenase-2 Inhibitor Celecoxib in the Treatment of Patients With Locally Advanced Carcinoma of the Cervix

Sponsor: NCIC Clinical Trials Group

Conditions Cervix Neoplasms

Interventions Celecoxib

Updated 5 times since 2017 Last updated: Feb 8, 2016 Started: Feb 28, 2001 Primary completion: Jan 31, 2011 Completion: Jan 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00152828, this PHASE1/PHASE2 trial focuses on Cervix Neoplasms and remains completed. Sponsored by NCIC Clinical Trials Group, it has been updated 5 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Feb 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NCIC Clinical Trials Group
Princess Margaret Hospital, Canada
University Health Network, Toronto

Data source: University Health Network, Toronto

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada